The news in black & white. Never grey.HEALTH

Health · FDA

FDA Rejects Summit’s Lung Cancer Drug Over Missing Survival Benefit

The agency said ivonescimab’s delay in disease progression was not enough without a statistically significant gain in overall survival; Summit says it will keep developing the drug.

Corridor on the second level - NÄL hospital 1
Photo: “Corridor on the second level - NÄL hospital 1” by W.carter, CC0, via Wikimedia Commons.

The Food and Drug Administration has declined to approve Summit Therapeutics’ experimental lung cancer drug ivonescimab, the company said Nov. 15 in an announcement summarized in an SEC filing. The agency issued a complete response letter, meaning the application cannot be approved in its present form. It sought approval, with platinum-based chemotherapy, for advanced non-small cell lung cancer in patients who had received an earlier EGFR-targeted drug.

According to Summit’s filing, the FDA determined that substantial evidence of effectiveness is not established without a statistically significant improvement in overall survival. It also said the benefit in progression-free survival, the time before a cancer worsens, did not by itself support a positive benefit-risk profile. Healio reported that in the phase 3 HARMONi trial of 438 patients, median progression-free survival was 6.8 months with ivonescimab versus 4.4 months with placebo, while median overall survival was 16.8 versus 14 months, a difference Healio described as not significant.

Summit Chairman and co-CEO Robert Duggan said the company was disappointed but that its determination to develop the drug had not changed, Healio reported. The rejection covers this one indication; Summit is running other trials of the drug.

Sources

  1. Summit Therapeutics Form 8-K (SEC), Nov. 15-16, 2026: complete response letter, indication, FDA’s stated reasoning <https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000092/smmt-20261115.htm>
  2. Healio, Nov. 16, 2026, Matthew Shinkle: HARMONi trial figures, Duggan statement <https://www.healio.com/news/hematology-oncology/20261116/fda-rejects-ivonescimab-for-egfrmutated-locally-advanced-or-metastatic-nsclc>

This article was drafted with AI writing tools from the sources listed, checked by a review pass, supervised by the paper’s editors and published by Daniel Varrone. Corrections: editor@monochromechronicles.com

More from Health

Recommended Reading

About this story: Compiled by the The Monochrome Chronicles desk from the sources listed above. Our standards · Report an error · Follow on YouTube

← More Health · Front page